Skip to main content

Lineage Cell Therapeutics, Inc.

LCTX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000876343

No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.

Superinvestors holding LCTX, Q2 2026

See all superinvestors

No superinvestor reported holding LCTX in Q2 2026.